[go: up one dir, main page]

WO2009115664A3 - Structure cristalline du domaine cc2-lz de nemo - Google Patents

Structure cristalline du domaine cc2-lz de nemo Download PDF

Info

Publication number
WO2009115664A3
WO2009115664A3 PCT/FR2009/000127 FR2009000127W WO2009115664A3 WO 2009115664 A3 WO2009115664 A3 WO 2009115664A3 FR 2009000127 W FR2009000127 W FR 2009000127W WO 2009115664 A3 WO2009115664 A3 WO 2009115664A3
Authority
WO
WIPO (PCT)
Prior art keywords
domain
nemo
crystalline structure
relates
crystallisation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2009/000127
Other languages
English (en)
Other versions
WO2009115664A2 (fr
Inventor
Fabrice Agou
Jeanne Chiaravalli
Stéphane DUQUERROY
Elisabeth Fontan
Olivera Grubisha
Monika Dorota Kaminska
Michel Veron
Florence Cordier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Institut Pasteur
Original Assignee
Laboratoires Servier SAS
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS, Institut Pasteur filed Critical Laboratoires Servier SAS
Priority to EP09722579A priority Critical patent/EP2240513A2/fr
Priority to CA2713884A priority patent/CA2713884A1/fr
Priority to JP2010545522A priority patent/JP5529759B2/ja
Priority to EA201001228A priority patent/EA020189B1/ru
Priority to AU2009227090A priority patent/AU2009227090B2/en
Priority to US12/735,671 priority patent/US8440790B2/en
Publication of WO2009115664A2 publication Critical patent/WO2009115664A2/fr
Publication of WO2009115664A3 publication Critical patent/WO2009115664A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Theoretical Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

Cristal du domaine CC2-LZ de la protéine NEMO dont la structure tri¬ dimensionnelle a été déterminée par diffraction des rayons X à une résolution d'environ 3.25 A. La présente invention concerne également des méthodes de cristallisation du domaine CC2-LZ. Les cristaux de CC2-LZ ainsi que l'information dérivés de leurs structures cristallines sont utilisés pour identifier et concevoir des composés qui entrent en interaction avec CC2-LZ.
PCT/FR2009/000127 2008-02-05 2009-02-05 Structure cristalline du domaine cc2-lz de nemo Ceased WO2009115664A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP09722579A EP2240513A2 (fr) 2008-02-05 2009-02-05 Structure cristalline du domaine cc2-lz de nemo
CA2713884A CA2713884A1 (fr) 2008-02-05 2009-02-05 Structure cristalline du domaine cc2-lz de nemo
JP2010545522A JP5529759B2 (ja) 2008-02-05 2009-02-05 Ｎｅｍｏのｃｃ２−ｌｚドメインの結晶構造
EA201001228A EA020189B1 (ru) 2008-02-05 2009-02-05 Кристаллическая структура сс2-lz домена nemo
AU2009227090A AU2009227090B2 (en) 2008-02-05 2009-02-05 Crystalline structure of the CC2-LZ domain of NEMO
US12/735,671 US8440790B2 (en) 2008-02-05 2009-02-05 Crystal structure of the CCZ-LZ domain of NEMO

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0800605A FR2927080A1 (fr) 2008-02-05 2008-02-05 Structure cristalline du domaine cc2-lz de nemo
FR08/00605 2008-02-05

Publications (2)

Publication Number Publication Date
WO2009115664A2 WO2009115664A2 (fr) 2009-09-24
WO2009115664A3 true WO2009115664A3 (fr) 2009-11-26

Family

ID=39638688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2009/000127 Ceased WO2009115664A2 (fr) 2008-02-05 2009-02-05 Structure cristalline du domaine cc2-lz de nemo

Country Status (9)

Country Link
US (1) US8440790B2 (fr)
EP (1) EP2240513A2 (fr)
JP (1) JP5529759B2 (fr)
AR (1) AR070555A1 (fr)
AU (1) AU2009227090B2 (fr)
CA (1) CA2713884A1 (fr)
EA (1) EA020189B1 (fr)
FR (1) FR2927080A1 (fr)
WO (1) WO2009115664A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864355B1 (en) * 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
WO2005027959A1 (fr) * 2003-09-24 2005-03-31 Institut Pasteur Inhibition selective de l'activation de nf-?b par des peptides conçus pour perturber l'oligomerisation de la proteine nemo

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101907A1 (en) * 2000-09-19 2004-05-27 Bussiere Dirksen E. Characterization of the gsk-3beta protein and methods of use thereof
ATE476443T1 (de) * 2003-02-27 2010-08-15 Max Planck Gesellschaft Kristallstruktur des ternären komplexes aus 14-3- 3, fusicoccin und plasma-membran atpase und methoden zum design neuer herbizide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864355B1 (en) * 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
WO2005027959A1 (fr) * 2003-09-24 2005-03-31 Institut Pasteur Inhibition selective de l'activation de nf-?b par des peptides conçus pour perturber l'oligomerisation de la proteine nemo
US20050220792A1 (en) * 2003-09-24 2005-10-06 Institut Pasteur Selective inhibition of NF-kappaB activation by peptides designed to disrupt NEMO oligomerization

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AGOU F ET AL: "Inhibition of NF-kB activation by peptides targeting NF-kB essential modulator (NEMO) oligomerization", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 279, no. 52, 24 December 2004 (2004-12-24), pages 54248 - 54257, XP002314352, ISSN: 0021-9258 *
AGOU F ET AL: "The trimerization domain of nemo is composed of the interacting C-terminal CC2 and LZ coiled-coil subdomains", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 279, no. 27, 2 July 2004 (2004-07-02), pages 27861 - 27869, XP002314350, ISSN: 0021-9258 *
BLUNDELL T L ET AL: "HIGH-THROUGHPUT CRYSTALLOGRAPHY FOR LEAD DISCOVERY IN DRUG DESIGN", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, BASINGSTOKE, GB, vol. 1, no. 1, 1 January 2002 (2002-01-01), pages 45 - 54, XP009023187, ISSN: 1474-1784 *
MAY M J ET AL: "Selective inhibition of NF-kB activation by a peptide that blocks the interaction of NEMO with the IkB kinase complex", SCIENCE, WASHINGTON, DC, vol. 289, 1 September 2000 (2000-09-01), pages 1550 - 1554, XP002189523, ISSN: 0036-8075 *
RUSHE M ET AL: "Structure of a NEMO/IKK-Associating Domain Reveals Architecture of the Interaction Site", STRUCTURE, CURRENT BIOLOGY LTD., PHILADELPHIA, PA, US, vol. 16, no. 5, 7 May 2008 (2008-05-07), pages 798 - 808, XP022665958, ISSN: 0969-2126, [retrieved on 20080506] *
SEBBAN-BENIN HÉLÈNE ET AL: "Identification of TRAF6-dependent NEMO polyubiquitination sites through analysis of a new NEMO mutation causing incontinentia pigmenti.", HUMAN MOLECULAR GENETICS 1 DEC 2007, vol. 16, no. 23, 1 December 2007 (2007-12-01), pages 2805 - 2815, XP002492548, ISSN: 0964-6906 *
WYLER EMANUEL ET AL: "Inhibition of NF-kappaB activation with designed ankyrin-repeat proteins targeting the ubiquitin-binding/oligomerization domain of NEMO", PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 16, no. 9, 1 September 2007 (2007-09-01), pages 2013 - 2022, XP008085017, ISSN: 0961-8368 *

Also Published As

Publication number Publication date
US20110159598A1 (en) 2011-06-30
EA201001228A1 (ru) 2011-04-29
US8440790B2 (en) 2013-05-14
CA2713884A1 (fr) 2009-09-24
FR2927080A1 (fr) 2009-08-07
EP2240513A2 (fr) 2010-10-20
AU2009227090A1 (en) 2009-09-24
WO2009115664A2 (fr) 2009-09-24
JP5529759B2 (ja) 2014-06-25
AR070555A1 (es) 2010-04-21
AU2009227090B2 (en) 2012-05-03
EA020189B1 (ru) 2014-09-30
JP2011516405A (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
WO2008057240A3 (fr) Anticorps anti-htnfalpha cristallisés
WO2008150946A8 (fr) Anticorps humanisés qui se lient au globulomère aβ(1-42) et leurs utilisations
WO2006127933A8 (fr) Procedes d'elaboration de forme i cristalline d'hydrochlorure de cinacalcet
IL192242A0 (en) Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides
EP1948732A4 (fr) Procede de preparation d'une composition liante bitumeuse
WO2007011907A3 (fr) Anticorps d'alpha-synucleine et techniques associees
WO2010065921A3 (fr) Conception d'anticorps à l'aide de structures cristallines d'anticorps anti-lipidiques
PL2266961T3 (pl) Proces syntezy związków organicznych
WO2010080242A3 (fr) Famille uzm-27 de compositions d'aluminosilicate cristallin, procédé de préparation des compositions et procédés d'utilisation des compositions
WO2011160827A3 (fr) Nouvelles molécules inhibitrices de jnk
ZA200905832B (en) Crystalline forms of an 8-azabicyclo [3.2.1] octane compound
IL209568A0 (en) Pyrimidine compound crystal or amorphous form and process for producing the same
WO2007149880A3 (fr) Structure cristalline du récepteur ox40l et ox40l complexé à ox40
WO2009037538A3 (fr) Procédé de préparation de lamivudine de forme i
HUE043068T2 (hu) Eljárás elágazó láncú szénhidrogén komponens elõállítására
WO2010027848A3 (fr) Formes de composés de lapatinib et procédés pour leur préparation
WO2009009103A3 (fr) Cristaux et structure du variant d'igg fc humain
WO2009115664A3 (fr) Structure cristalline du domaine cc2-lz de nemo
IL186499A (en) Processes for the preparation of a crystalline form of atorostatin mycelium
EA200900936A1 (ru) Аморфные и кристаллические формы ривастигмина гидротартрата
EP2177495A4 (fr) Procédé de production d'un composé de triphénylène et cristaux obtenus par ledit procédé
ZA200709621B (en) Process for the synthesis of organic compounds
GB0721160D0 (en) New method for diagnosing sjogren's syndrome
FR2894596B1 (fr) Procede d'autocalibration de biopuces
EP1870408A4 (fr) Procede innovant de production de ramosetron ou de son sel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09722579

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009722579

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009227090

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2713884

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010545522

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009227090

Country of ref document: AU

Date of ref document: 20090205

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201001228

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 12735671

Country of ref document: US